Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: A randomized, double-blind, placebo-controlled, cross-over, Phase i study

Endocrine

Volumn 42, Issue 2, 2012, Pages 366-374

  Beglinger, Christoph ^a   Hu, Ke ^b   Wang, Ying ^b   Bouillaud, Emmanuel ^b   Darstein, Christelle ^b   Wang, Yanfeng ^b   Mohideen, Pharis ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Healthy volunteers; Pasireotide; Pharmacokinetics; Safety; Tolerability

Indexed keywords

CHOLECYSTOKININ; GASTRIN; GLUCOSE; GROWTH HORMONE; PASIREOTIDE; PLACEBO; THYROID HORMONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; GALLBLADDER; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HALITOSIS; HORMONE INHIBITION; HUMAN; HUMAN EXPERIMENT; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEG CRAMP; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCLE DISEASE; MUSCLE FIBRILLATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; XEROSTOMIA;

EID: 84867403297     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9668-1     Document Type: Article

References (31)

1. U. Kumar, Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 40, 168-180 (2011)
2. A. Ben-Shlomo, H. Schmid, K. Wawrowsky et al., Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94, 4342-4350 (2009)
3. C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707-716 (2002)
4. H.A. Schmid, Pasireotide (SOM230): development, mechanism of action and potential applications. Mol. Cell. Endocrinol. 286, 69-74 (2008)
5. J. Van Der Hoek, W.W. de Herder, R.A. Feelders et al., A singledose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. 89, 638-645 (2004)
6. I. Donangelo, S. Melmed, Treatment of acromegaly: future. Endocrine 28, 123-128 (2005)
7. L. Kvols, J.E. Glusman, E.A. Hahn et al., The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J. Clin. Oncol. 25(18S), abst 4558 (2007)
8. L. Kvols, B. Wiedenmann, K. Oberg et al., Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a Phase II study. ASCO Gastrointestinal Cancers Symposium, San Francisco, 26-28 January 2006, abst 171
9. K.I. Alexandraki, G. Kaltsas, Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 41, 40-52 (2012)
10. L.J. Hofland, S.W. Lamberts, The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24, 28-47 (2003)
11. L.J. Hofland, J. Van Der Hoek, R. Feelders et al., The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 152, 645-654 (2005)
12. D.L. Batista, X. Zhang, R. Gejman et al., The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 91, 4482-4488 (2006)
13. Y. Horsmans, K. Hu, M. Ruffin et al., Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter Phase I study. J. Clin. Pharmacol. 52, 552-558 (2012)
14. P. Ma, Y. Wang, J. Van Der Hoek et al., Pharmacokineticpharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin. Pharmacol. Ther. 78, 69-80 (2005)
15. S. Petersenn, N. Unger, K. Hu et al., Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J. Clin. Pharmacol. doi: 10.1177/0091270011408727, [Epub ahead of print] (2011)
16. S. Petersenn, K. Hu, M. Maldonado et al., Tolerability and doseproportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin. Ther. 34, 677-688 (2012)
17. M. Shenouda, M. Maldonado, Y. Wang et al., An open-label, dose-escalation study of once- and twice-daily pasireotide in healthy volunteers: safety, tolerability and effects on glucose, insulin and glucagon levels. Am. J. Ther. (2012 in press)
18. M. Boscaro, W.H. Ludlam, B. Atkinson et al., Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial. J. Clin. Endocrinol. Metab. 94, 115-122 (2009)
19. M. Boscaro, Y. Zhang, K. Sen et al., Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study. Endocr. Rev. 31(3 Suppl 1), S333, abst P1-274 (2010)
20. M. Bronstein, F. Gu, C.-C. Shen et al. A randomized, blinded, multicenter, Phase III study to assess the efficacy and safety of pasireotide LAR versus octreotide LAR in patients with active acromegaly. 14th European NeuroEndocrine Association Congress, Liege, 22-25 September 2010, abst OC-6.1
21. A. Colao, J. Fleck, S. Pain et al., Pasireotide LAR versus octreotide LAR or lanreotide autogel in patients with inadequately controlled acromegaly: a Phase III, multicenter, randomized, parallel-group study. 14th European Neuroendocrine Association Congress, Liege, 22-25 September 2010, abst OC-6.2
22. A. Colao, S. Petersenn, J. Newell-Price et al., A 12-month Phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366, 914-924 (2012)
23. L. Kvols, K. Oberg, T.M. O'Dorisio et al., Efficacy, safety and pharmacokinetic results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR. Neuroendocrinology 92(1), abst C57 (2010)
24. S. Petersenn, J. Schopohl, A. Barkan et al., Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J. Clin. Endocrinol. Metab. 95, 2781-2789 (2010)
25. H. Dietrich, K. Hu, M. Ruffin et al., Safety, tolerability and pharmacokinetics of a single dose of pasireotide long-acting release (LAR) in healthy volunteers: a single-center Phase I study. Eur. J. Endocrinol. doi:10.1530/EJE-11-0773, [Epub ahead of print] (2012)
26. Metropolitan Life Insurance Company, Metropolitan height and weight tables. Stat. Bull. 64, 2-9 (1983)
27. H. Boxenbaum, M. Battle, Effective half-life in clinical pharmacology. J. Clin. Pharmacol. 35, 763-766 (1995)
28. B.P. Smith, F.R. Vandenhende, K.A. DeSante et al., Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17, 1278-1283 (2000)
29. J. Hasskarl, M. Kaufmann, H.A. Schmid, Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol. 7, 895-913 (2011)
30. G. Mazziotti, C. Gazzaruso, A. Giustina, Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22, 499-506 (2011)
31. R.R. Henry, S. Mudaliar, K. Wetli-Hermosillo et al., Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocr. Rev. 32(03), abst P3-274 (2011)